Development of PRO-140 (Leronlimab) as a treatment for COVID-19 (Record no. 76035)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01860nim a2200445 a 4500 |
| 001 - CONTROL NUMBER | |
| control field | HST8159 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | UkLoHST |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o h |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr nna|||||||| |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | sr |mnnnnnzne| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 200504s2020 enk|||||o||h||||||||eng d |
| 028 50 - PUBLISHER NUMBER | |
| Publisher number | 8159 |
| Source | Henry Stewart Talks |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (UkLoHST)4246 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | UkLoHST |
| Language of cataloging | eng |
| Transcribing agency | UkLoHST |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Lalezari, Jacob, |
| Affiliation | (Quest Clinical Research, USA) |
| Relator code | spk |
| 245 10 - TITLE STATEMENT | |
| Title | Development of PRO-140 (Leronlimab) as a treatment for COVID-19 |
| Medium | [electronic resource] / |
| Statement of responsibility, etc. | Jacob Lalezari. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
| Place of publication, distribution, etc. | London : |
| Name of publisher, distributor, etc. | Henry Stewart Talks, |
| Date of publication, distribution, etc. | 2020. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (1 streaming audio file (20 min.)). |
| 490 1# - SERIES STATEMENT | |
| Series statement | Interviews on Covid-19, |
| International Standard Serial Number | 2056-452X |
| 500 ## - GENERAL NOTE | |
| General note | Audio interview. |
| 500 ## - GENERAL NOTE | |
| General note | Title from title frames. |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Contents: Previous indications for Leronlimab -- Leronlimab is a CCR5 receptor antagonist -- CCR5 receptor function in inflammation and disease -- Clinical limitations of blocking CCR5 receptors -- How will Leronlimab be used in the clinic? -- When can we expect a preliminary approval? |
| 506 ## - RESTRICTIONS ON ACCESS NOTE | |
| Terms governing access | Access restricted to subscribers. |
| 538 ## - SYSTEM DETAILS NOTE | |
| System details note | Mode of access: World Wide Web. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Coronavirus infections |
| General subdivision | Treatment. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | COVID-19 (Disease) |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Drug development. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | CCR5 Receptor Antagonists |
| General subdivision | therapeutic use. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Coronavirus Infections |
| General subdivision | drug therapy. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | COVID-19 |
| General subdivision | drug therapy. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Drug Development. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Inflammation. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | leronlimab. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Pharmaceutical Preparations. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Receptors, CCR5. |
| 650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | SARS-CoV-2. |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
| Uniform title | Henry Stewart talks. |
| Name of part/section of a work | Biomedical & life sciences collection. |
| -- | Interviews on Covid-19. |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://hstalks.com/bs/4246/">https://hstalks.com/bs/4246/</a> |
| 856 42 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://hstalks.com/bs/p/1060/">https://hstalks.com/bs/p/1060/</a> |
| Materials specified | Series |
No items available.